Second Sight Medical Products Inc  

(Public, NASDAQ:EYES)   Watch this stock  
Find more results for eyes
-0.18 (-3.56%)
After Hours: 4.88 0.00 (0.00%)
Dec 1, 4:52PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.80 - 5.11
52 week 4.57 - 19.63
Open 5.06
Vol / Avg. 285,944.00/441,647.00
Mkt cap 179.27M
P/E     -
Div/yield     -
EPS -0.95
Shares 35.85M
Beta     -
Inst. own 20%
Oct 29, 2015
Q3 2015 Second Sight Medical Products Inc Earnings Call
Oct 29, 2015
Q3 2015 Second Sight Medical Products Inc Earnings Release
Sep 9, 2015
Second Sight Medical Products Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -209.54% -1035.99%
Operating margin -209.38% -829.59%
EBITD margin - -616.69%
Return on average assets -53.30% -126.30%
Return on average equity -71.15% -277.21%
Employees 121 -
CDP Score - -


12744 San Fernando Road, Bldg. 3
SYLMAR, CA 91342
United States - Map
+1-818-8335000 (Phone)
+1-818-8335067 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Second Sight Medical Products, Inc. is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant, a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU), and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada, Turkey, and at one medical center in Saudi Arabia.

Officers and directors

Robert J. Greenberg M.D., Ph.D. Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Will McGuire President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Thomas B. Miller Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Anthony Moses Commercial Vice President - Americas
Age: 56
Bio & Compensation  - Reuters
Edward David Randolph Vice President - Manufacturing
Age: 57
Bio & Compensation  - Reuters
Anne-Marie Juliette Ripley Vice President - Clinical and Regulatory Affairs
Age: 45
Bio & Compensation  - Reuters
Gregoire Cosendai Vice President - European Operations
Age: 43
Bio & Compensation  - Reuters
James K. Miller Director - Manufacturing
Bio & Compensation  - Reuters
Alfred E. Mann Chairman Emeritus
Age: 89
Bio & Compensation  - Reuters
William J. Link Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters